Quick Comparison
| CJC-1295 (no DAC) | Epithalon | |
|---|---|---|
| Half-Life | 0.5 hours | 2-4 hours |
| Typical Dosage | Standard: 100-300 mcg subcutaneous once to three times daily, typically before bed and/or upon waking. Often combined with Ipamorelin 200-300 mcg in the same injection. Cycled 5 days on, 2 days off, or continuously for 8-12 weeks. | Standard: 5-10 mg subcutaneous once daily for 10-20 days. Cycled two or three times per year. Some protocols use 10 days on, followed by a 4-6 month break before repeating. |
| Administration | Subcutaneous injection | Subcutaneous or intravenous injection |
| Research Papers | 0 papers | 4 papers |
| Categories |
Mechanism of Action
CJC-1295 (no DAC)
CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (at positions 2, 8, 15, and 27) have been made to increase resistance to enzymatic degradation while preserving full biological activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary.
When CJC-1295 binds the GHRH receptor, it activates the Gs alpha subunit, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors that drive GH gene expression and secretion. Importantly, this mechanism preserves the natural pulsatile pattern of GH release because it works within the existing hypothalamic-pituitary feedback loop — somatostatin still provides inhibitory regulation between pulses.
The key advantage of the no-DAC version over the DAC version is this preservation of pulsatility. Because its half-life is approximately 30 minutes, it produces a discrete GH pulse that rises and falls naturally, mimicking the body's own secretory pattern. This pulsatile pattern is believed to be physiologically superior to sustained elevation because GH receptor sensitivity is maintained between pulses, and the liver's IGF-1 production response is optimized by intermittent rather than continuous GH stimulation. This is why CJC-1295 (no DAC) is often preferred by practitioners despite requiring more frequent dosing.
Epithalon
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on epithalamin, a peptide extract from the pineal gland first studied by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary reported mechanism is the activation of telomerase — the ribonucleoprotein enzyme complex responsible for maintaining telomere length at chromosome ends.
Telomeres are repetitive nucleotide sequences (TTAGGG in humans) that cap and protect chromosome ends from degradation, fusion, and recognition as DNA damage. With each cell division, the DNA replication machinery cannot fully copy the very end of the lagging strand (the 'end replication problem'), resulting in progressive telomere shortening. When telomeres reach a critical length, cells enter replicative senescence (permanent growth arrest) or apoptosis — a fundamental mechanism of cellular aging. Telomerase, composed of the catalytic subunit hTERT (human telomerase reverse transcriptase) and the RNA template component hTR/TERC, can add TTAGGG repeats back to chromosome ends, counteracting this shortening.
Epithalon reportedly activates the expression of the hTERT gene, increasing telomerase activity in somatic cells. In cell culture studies, epithalon treatment was associated with increased telomere length and extended replicative lifespan in human fibroblasts and retinal pigment epithelial cells. The peptide also reportedly stimulates melatonin production by the pineal gland, potentially through gene-regulatory effects on pineal cells. Melatonin itself is a potent antioxidant and circadian regulator, and its decline with age correlates with numerous age-related changes. Additional reported effects include normalization of T-cell function, modulation of neuroendocrine signaling, and improved antioxidant enzyme expression. It should be noted that the majority of published research comes from Russian institutions, and large-scale, peer-reviewed Western clinical trials are lacking.
Risks & Safety
CJC-1295 (no DAC)
Common
facial flushing, headache, dizziness, injection site irritation.
Serious
overworking the pituitary gland with excessive doses, theoretical risk of promoting existing tumours through elevated growth hormone.
Rare
allergic reactions, fainting.
Epithalon
Common
irritation at the injection site, mild headache, brief drowsiness.
Serious
activating telomerase could promote pre-cancerous or cancerous cells; most research comes from Russian institutions with limited Western clinical data.
Rare
allergic reactions.
Full Profiles
CJC-1295 (no DAC) →
One of the most popular growth hormone peptides, often called Mod GRF 1-29. Instead of injecting growth hormone directly, this tells your pituitary gland to release more of its own GH naturally. This is considered healthier than injecting GH directly because your body keeps its normal feedback systems intact. Usually combined with Ipamorelin for much stronger effects — the two work together better than either alone.
Epithalon →
A lab-made peptide based on a natural compound from the pineal gland (a small gland in your brain). It's studied for its ability to activate telomerase, the enzyme that keeps the protective caps on the ends of your chromosomes from shortening. Since those caps naturally shorten as cells age, this peptide is one of the most talked-about in anti-aging research. Originally developed in Russia.